Coronary disease & ACSCohort study
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention
- Retrospective cohort study
- nationwide cohort database
- stabilized inverse probability of treatment weighting
Authors' conclusion
In clinical practice, combination lipid-lowering therapy with ezetimibe and moderate-intensity statin was associated with favorable clinical outcomes and drug compliance in patients treated with drug-eluting stent implantation.
Study context
- Population
- Patients prescribed rosuvastatin after drug-eluting stent implantationafter IPTW
- Participants
- 72,050 patients
- Exposure
- Combination lipid-lowering therapy vs High-intensity statin monotherapy
- Combination lipid-lowering therapyn = 10,794
- High-intensity statin monotherapyn = 61,256reference
- Outcome
- Composite of:
- CV death
- MI
- Coronary revascularization
- Hospitalization for HF treatment
- Nonfatal stroke (as in RACING)
- Follow-up
- 3 years
Main finding
As reported in the abstract
Hazard ratio
0.75
95% CI 0.70–0.79
P < 0.001
By group
Combination lipid-lowering therapy vs High-intensity statin monotherapy
HR 0.75 (95% CI 0.70–0.79); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Combination lipid-lowering therapy | High-intensity statin monotherapy | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Statin discontinuation | 6.5% | 7.6% | 0.85 (0.78–0.94) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Safety
| Outcome | Combination lipid-lowering therapy | High-intensity statin monotherapy | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| New-onset DM requiring medication | 7.7% | 9.6% | 0.80 (0.72–0.88) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. Published 1 August 2023. doi:10.1016/j.jacc.2023.05.042
Summarised from the published abstract; every number is checked against it